CTSO is already approved in Europe and other parts of the world and if any CAR-T-cell company or a clinic participating in this Car-T-Cell therapy wants to use the filter and possibly has to, it will make this easy and for this one does not need a partnership agreement between eg Novartis and cytosorbents.
The sales commission for the possible use of the filter ends up anyway with the contractual distribution partner, so what advantage would have for example a partnership with novartis ?